Table 1.

Characteristics of MCC patients treated with SMBT for in-transit cutaneous metastases

Patient No	Sex, age at diagnosis (yr)	Primary site	AJCC stage at diagnosis	Initial treatment (pre-SMBT)	Time to relapse* (mo**)	Chemo for in-transit metastases, No of chemo regimens (pre-SMBT)	SMBT (cGy)	In-field recurrence, time to recurrence (mo)	Site of other recurrence (time to recurrence (mo))	SMBT for additional in-transit metastases	Total lesions treated	Follow-up (mo**)	Status
1	M, 70	R calf	IIA	WLE, LR-RT	8	N	1200	Y, 25	In-Transit (19, 28), Distant (19)	N	11	42	DOD
2	M, 72	R groin	IIIB	Chemo, R-RT	12	Y, 2	1200	N	In-Transit (85)	Y	8	85	AWOD
3	M, 76	R forehead	IIIA	WLE, LR-RT, chemo	11	N	1200	N	Regional (25, 26), Distant (36)	N	4	36	AWD
4	M, 81	L forehead	IIIA	WLE, LR-RT	10	N	1200	N	Regional (23), Distant (27)	N	2	32	AWD
5	F, 63	L calf	IIIA	WLE, LR-RT, chemo	7	Y, 1	1200	N	In-Transit (13,15)	Y	13	39	AWOD
6	M, 63	R thigh	IIA	WLE, LR-RT, chemo	9	N	1200	Y, 2	In-Transit (16, 18, 19, 21, 24), Regional (24), Distant (24)	Y	37	31	DOD
7	F, 87	R calf	IB	WLE	6	N	1200	N	In-Transit (7, 15), Regional (12)	Y	3	26	AWOD
8	F, 83	L forearm	IB	WLE	1	N	1200	N	In-Transit (3, 5, 17, 20), Regional (20) Distant (5)	Y	29	22	DOD
9	F, 76	R foot	IIIB	WLE, LR-RT, S-RT	7	N	1200	N	In-Transit (7, 11.5, 18), Regional (12), Distant (22)	N	9	24	DOD
10	M, 79	L calf	IIIB	WLE	45	N	1000	N	In-Transit (45, 47, 49), Regional (49), Distant (58)	N	36	58	AWD

^*The initial site of relapse for all patients was in-transit cutaneous metastases

^**Calculated from the time of diagnosis

^***WLE, wide local excision; LR-RT, loco-regional radiation therapy; R-RT, regional radiation therapy; S-RT, salvage radiation therapy; chemo, chemotherapy; AWOD, alive without disease; AWD, alive with disease; DOD, died of disease